Literature DB >> 7471083

Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.

R Ganapathi, A Krishan, I Wodinsky, C G Zubrod, L J Lesko.   

Abstract

1-beta-D-Arabinofuranosylcytosine (ara-C) was encapsulated in anionic multilamellar liposomes prepared with different lecithin: cholesterol (L:C) ratios. The chemotherapeutic activity of encapsulated ara-C was compared with comparable doses of ara-C in 0.85% saline solution (single- and multiple-dose schedules) in mice bearing L1210 (i.p.) leukemia. Maximum survival was obtained in animals given injections of ara-C (40 mg/kg) encapsulated in liposomes with a L:C ratio of 1:1. The effect of L:C ratio on survival was not pronounced in multiple-dose schedules. Multiple doses (every 4.5 hr for 3 separate injections) of 40 mg/kg with L:C ratios of 1:1 and 1:0.5 were toxic, resulting in 83 and 50% mortality, respectively, of mice by Day 7. This study shows that drug efflux and in vivo antitumor activity and toxicity of encapsulated ara-C is influenced by the cholesterol content of the liposomal lipid bilayer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471083

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors:  P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.

Authors:  S Kim; D J Kim; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

Authors:  E A Forssen; Z A Tökès
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

6.  Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes.

Authors:  J W Babbage; M C Berenbaum
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

7.  Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.

Authors:  V J Richardson; G A Curt; B E Ryman
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

Review 8.  Immunological and Toxicological Considerations for the Design of Liposomes.

Authors:  Collin T Inglut; Aaron J Sorrin; Thilinie Kuruppu; Shruti Vig; Julia Cicalo; Haroon Ahmad; Huang-Chiao Huang
Journal:  Nanomaterials (Basel)       Date:  2020-01-22       Impact factor: 5.076

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.